Clinical Trial Update: Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) [Phase 3]

View source ↗

Summary

This entry reports the completion of a Phase 3 trial evaluating VEGF Trap-Eye (aflibercept) for macular edema due to central retinal vein occlusion. Results wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Retinal Vein Occlusion

Drugs mentioned

• VEGF Trap-Eye (aflibercept)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Macular Edema Secondary to Central Retinal Vein Occlusion | Phase 3 | Status: COMPLETED | Results posted: 2013-05-27